Review
Biochemistry & Molecular Biology
Federica Biello, Francesca Platini, Francesca D'Avanzo, Carlo Cattrini, Alessia Mennitto, Silvia Genestroni, Veronica Martini, Paolo Marzullo, Gianluca Aimaretti, Alessandra Gennari
Summary: Breast cancer and host metabolism are closely related, with insulin playing a role in promoting tumor growth through various pathways, while metformin's anti-cancer mechanisms involve lowering insulin levels and direct impact on cancer cell signaling pathways. Obesity, metabolic syndrome, and insulin resistance are all implicated in breast cancer growth and prognosis, potentially linked to a pro-inflammatory state and cytokines originating from fat tissue.
Article
Endocrinology & Metabolism
Anamil Khiyami, Neha Mehrotra, Sharini Venugopal, Hussain Mahmud, Georgios. A. A. Zenonos, Paul. A. A. Gardner, Pouneh. K. K. Fazeli
Summary: This study aims to investigate the relationship between obesity and serum IGF-1 levels in patients with pituitary adenomas. The results showed a significant positive association between BMI and IGF-1 in patients with acromegaly. Compared to patients with nonfunctioning adenomas, patients with acromegaly had significantly higher levels of IGF-1.
Article
Endocrinology & Metabolism
Mirela-Diana Ilie, Antoine Tabarin, Alexandre Vasiljevic, Jean-Francois Bonneville, Lucile Moreau-Grange, Franck Schillo, Brigitte Delemer, Anne Barlier, Dominique Figarella-Branger, Segolene Bisot-Locard, Alexandre Santos, Philippe Chanson, Gerald Raverot
Summary: This study aimed to explore the factors related to SRLs in the treatment of acromegaly and confirmed that SST2A and adenoma granularity are good predictors of response to octreotide. In addition, the optimization of MRI sequences is important for using T2WSI as a predictor of treatment response.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Medicine, General & Internal
Amit Akirov, Hiba Masri-Iraqi, Idit Dotan, Ilan Shimon
Summary: The diagnosis, management, and treatment of acromegaly heavily rely on the levels of serum IGF-1, basal GH, and nadir GH following OGTT. However, these hormone concentrations can be influenced by various factors, leading to discordant levels that may require additional monitoring and data. New standards for GH and IGF-1 provide more accurate tools, but limitations should be considered along with clinical history and imaging studies when evaluating patients with acromegaly.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Betina Biagetti, Pedro Iglesias, Rocio Villar-Taibo, Maria-Dolores Moure, Miguel Paja, Marta Araujo-Castro, Jessica Ares, Cristina Alvarez-Escola, Almudena Vicente, Elia Alvarez Guivernau, Iria Novoa-Testa, Fernando Guerrero Perez, Rosa Camara, Beatriz Lecumberri, Carlos Garcia Gomez, Ignacio Bernabeu, Laura Manjon, Sonia Gaztambide, Fernando Cordido, Susan M. Webb, Edelmiro Luis Menendez-Torre, Juan J. Diez, Rafael Simo, Manel Puig-Domingo
Summary: The study found that the most common phenotype in elderly patients newly diagnosed with acromegaly includes small adenomas and moderately high IGF-1 levels. GH <= 6 ng/ml at diagnosis and female gender, rather than age per se, were associated with a greater chance of response to SRL.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Lukasz Mizera, Jowita Halupczok-Zyla, Katarzyna Kolackov, Agnieszka Zembska, Jedrzej Grzegrzolka, Diana Jedrzejuk, Marek Bolanowski, Jacek Daroszewski
Summary: The study found that irisin levels were significantly lower in acromegaly patients compared to controls, suggesting impaired hormonal muscle function contributing to metabolic complications in this disorder. On the other hand, myostatin does not appear to play a critical role in regulating muscle mass in acromegaly. Further studies are needed to better understand the relationship between myostatin and growth hormone in acromegaly.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
David R. Clemmons, Martin Bidlingmaier
Summary: Standard treatment for acromegaly focuses on achieving specific levels of growth hormone (GH) and insulin-like growth factor (IGF-I). However, the appropriateness of these targets is not well-defined. GH measurements indicate tumor size changes, while failure in GH suppression after glucose stimulation is associated with tumor recurrence. IGF-I levels are closely associated with symptom and sign changes. Lowering GH and IGF-I concentrations is linked to increased longevity, although only GH increase has been analyzed in detail. Lowering GH and IGF-I consistently leads to improved outcomes, but previous studies' reported absolute levels are now out-of-date.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Luigi Maione, Cristina Albrici, Solange Grunenwald, Celine Mouly, Vincenzo Cimino, Anne-Lise Lecoq, Jean Claude Souberbielle, Philippe Caron, Philippe Chanson
Summary: This study compared the serum IGF-I dynamics and variability in patients treated with SRLs, surgically cured patients, and healthy controls. The results showed that IGF-I decreased significantly at Day 7 and Day 14 after injection in SRL-treated patients, but remained stable in cured patients and healthy controls. In addition, SRL-treated patients had higher IGF-I variability, especially in nonoptimally controlled patients. The measurement at the farthest distance from SRL injection was the best predictor of optimal disease control.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Charlott Hoerenz, Mandy Vogel, Kerstin Wirkner, Uta Ceglarek, Joachim Thiery, Roland Pfaeffle, Wieland Kiess, Juergen Kratzsch
Summary: This study examines the effects of BMI, contraceptive drugs, and hormone replacement therapy on serum levels of IGF-I and IGFBP-3. The results indicate that obesity and contraceptive drugs can influence the levels of IGF-I and IGFBP-3 in different age groups.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Malgorzata Rolla, Aleksandra Jawiarczyk-Przybylowska, Jowita Halupczok-Zyla, Marcin Kaluzny, Bogumil M. Konopka, Izabela Bloniecka, Grzegorz Zielinski, Marek Bolanowski
Summary: Acromegaly patients, predominantly female, commonly suffer from complications such as metabolic disorders, cardiovascular diseases, and endocrine disorders. A majority of patients demonstrate a coexistence of cardiac, metabolic, and endocrine disturbances, with a small percentage being disease-free in these main groups.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Tomoko Okuyama, Mayu Kyohara, Yasuo Terauchi, Jun Shirakawa
Summary: IGFs mainly mediate long-term actions in cell fates, while insulin predominantly exerts its role on metabolic activities. The interactions between insulin receptor signaling and IGF-I receptor signaling in metabolism and cell fates are complicated, and the function of IGF-I in respective tissues remains insufficiently understood. Clarifying the precise roles of IGF-I signaling on metabolism separate from those of insulin signaling is necessary.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Endocrinology & Metabolism
Pamela U. Freda
Summary: Acromegaly is a hormonal disorder characterized by excess hormone production, leading to a specific lipodystrophy and insulin resistance. Understanding the pathophysiology of this condition and its effects on adipose tissue metabolism and insulin resistance is important for optimizing treatment and long-term outcomes for patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Melpomeni Moustaki, Stavroula A. Paschou, Paraskevi Xekouki, Kalliopi Kotsa, Melpomeni Peppa, Theodora Psaltopoulou, Sophia Kalantaridou, Andromachi Vryonidou
Summary: Secondary diabetes mellitus (DM) is a common complication of acromegaly, with a prevalence of up to 55% in cases. Conversely, the prevalence of acromegaly is higher in patients with type 2 DM (T2DM). Secondary DM is primarily dependent on the status of acromegaly and is associated with increased cardiovascular morbidity, malignancy rate, and overall mortality. The main pathophysiologic mechanism is increased insulin resistance due to excessive lipolysis and altered fat distribution, accompanied by intermuscular fat and dysfunctional adipose tissue. Insulin resistance is attributed to the diabetogenic effects of growth hormone (GH), which outweigh the insulin-sensitizing effects of insulin-like growth factor 1 (IGF-1), possibly due to higher glucometabolic potency of GH, IGF-1 resistance, or both. GH and IGF-1 act synergistically in increasing insulin secretion. Hyperinsulinemia in the portal vein leads to enhanced responsiveness of liver GH receptors and IGF-1 production, indicating a mutually amplifying loop between the GH-IGF-1 axis and insulin. Secondary DM develops due to beta cell exhaustion, primarily caused by gluco-lipo-toxicity. Somatostatin analogues inhibit insulin secretion, especially pasireotide (PASI), which impairs glycemic profile in up to 75% of cases, establishing a separate pathophysiologic entity, PASI-induced DM. Conversely, pegvisomant and dopamine agonists improve insulin sensitivity. In turn, metformin, pioglitazone, and sodium-glucose transporters 2 inhibitors may modify the disease by counteracting hyperinsulinemia or exerting pleiotropic effects. Large prospective cohort studies are needed to validate these concepts and define optimal DM management in acromegaly.
Article
Endocrinology & Metabolism
Ilan Shimon, Zaina Adnan, Dania Hirsch, Hadar Duskin-Bitan, Amit Akirov
Summary: Subclinical acromegaly is a rare condition that is often undiagnosed, but most patients experience clinical improvement after treatment.
Review
Endocrinology & Metabolism
Marek Bolanowski, Zaina Adnan, Mirjana Doknic, Mykola Guk, Vaclav Hana, Irena Ilovayskaya, Darko Kastelan, Tomaz Kocjan, Martin Kuzma, Akmaral Nurbekova, Catalina Poiana, Nikolette Szucs, Silvia Vandeva, Roy Gomez, Sorin Paidac, Damien Simoneau, Ilan Shimon
Summary: Acromegaly is a rare condition caused by benign pituitary adenomas, and there are marked differences in its management among different countries. Improving coordination and participation in acromegaly registries are crucial for optimizing patient care.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Nurgul Bozkurt, Sueleyman Utku Uzun, Ali Ishan Bozkurt, Sebahat Turgut
Summary: This study aimed to investigate the impact of smoking cessation on the risk of cardiovascular disease in workers. The results showed that within 6 months after quitting smoking, the risk score and CVD risk of employees decreased, and the reduction in coronary heart disease risk was greater in quitters.
Meeting Abstract
Respiratory System
Nurgul Bozkurt, Suleyman Utku Uzun, Ali Ihsan Bozkurt, Sebahat Turgut
Article
Medicine, General & Internal
Yasemin Korkut, Alime Emre, Ceylan Ayada
KONURALP TIP DERGISI
(2019)
Article
Pharmacology & Pharmacy
Nurgul Bozkurt, Fatih Altintas, Ali Ihsan Bozkurt, Gunfer Turgut, Sebahat Turgut
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2019)
Meeting Abstract
Physiology
Ceylan Ayada, Umran Toru Erbay, Hasan Simsek, Ozlem Arik
Meeting Abstract
Physiology
Ceylan Ayada, Umran Toru Erbay, Hasan Simsek
Meeting Abstract
Physiology
Umran Toru Erbay, Ceylan Ayada, Hasan Simsek, Ozlem Arik
Article
Rehabilitation
Melek Tunc-Ata, Mukaddes Mergen-Dalyanoglu, Sebahat Turgut, Gunfer Turgut
JOURNAL OF EXERCISE REHABILITATION
(2017)
Meeting Abstract
Physiology
M. Tunc-Ata, F. Altintas, G. Turgut, S. Turgut
Meeting Abstract
Physiology
N. Bozkurt, F. Altintas, A. I. Bozkurt, G. Turgut, S. Turgut
Article
Medicine, Research & Experimental
Senay Topsakal, Fulya Akin, Sabahat Turgut, Emrah Yerlikaya, Guzin F. Yaylali
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
(2017)
Article
Rehabilitation
Melek Tunc-Ata, Gunfer Turgut, Mukaddes Mergen-Dalyanoglu, Sebahat Turgut
JOURNAL OF EXERCISE REHABILITATION
(2017)
